These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34669238)

  • 1. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.
    Yan W; Chung CY; Xie T; Ozeck M; Nichols TC; Frey J; Udyavar AR; Sharma S; Paul TA
    Mol Oncol; 2022 Mar; 16(6):1309-1328. PubMed ID: 34669238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
    Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
    Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jumonji histone demethylases are therapeutic targets in small cell lung cancer.
    Nguyen A; Nuñez CG; Tran TA; Girard L; Peyton M; Catalan R; Guerena C; Avila K; Drapkin BJ; Chandra R; Minna JD; Martinez ED
    Oncogene; 2024 Sep; 43(38):2885-2899. PubMed ID: 39154123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
    Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
    J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
    Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
    Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1.
    Chen HY; Durmaz YT; Li Y; Sabet AH; Vajdi A; Denize T; Walton E; Laimon YN; Doench JG; Mahadevan NR; Losman JA; Barbie DA; Tolstorukov MY; Rudin CM; Sen T; Signoretti S; Oser MG
    Nat Commun; 2022 Aug; 13(1):4998. PubMed ID: 36008402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
    Fang Y; Liao G; Yu B
    J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing.
    Redin E; Sridhar H; Zhan YA; Pereira Mello B; Zhong H; Durani V; Sabet A; Manoj P; Linkov I; Qiu J; Koche RP; de Stanchina E; Astorkia M; Betel D; Quintanal-Villalonga Á; Rudin CM
    J Hematol Oncol; 2024 Jul; 17(1):58. PubMed ID: 39080761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
    Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
    Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
    Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
    Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
    Hiatt JB; Sandborg H; Garrison SM; Arnold HU; Liao SY; Norton JP; Friesen TJ; Wu F; Sutherland KD; Rienhoff HY; Martins R; Houghton AM; Srivastava S; MacPherson D
    Clin Cancer Res; 2022 Oct; 28(20):4551-4564. PubMed ID: 35920742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
    Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
    Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
    Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
    Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.
    Tlemsani C; Pongor L; Elloumi F; Girard L; Huffman KE; Roper N; Varma S; Luna A; Rajapakse VN; Sebastian R; Kohn KW; Krushkal J; Aladjem MI; Teicher BA; Meltzer PS; Reinhold WC; Minna JD; Thomas A; Pommier Y
    Cell Rep; 2020 Oct; 33(3):108296. PubMed ID: 33086069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.
    Stewart CA; Byers LA
    Cancer Cell; 2015 Jul; 28(1):4-6. PubMed ID: 26175409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taking SCLC on a Bad LSD(1) Trip One NOTCH Further.
    Kim J; Sage J
    Trends Mol Med; 2019 Apr; 25(4):261-264. PubMed ID: 30852141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer.
    Jotatsu T; Yagishita S; Tajima K; Takahashi F; Mogushi K; Hidayat M; Wirawan A; Ko R; Kanemaru R; Shimada N; Mitani K; Saito T; Takamochi K; Suzuki K; Kohsaka S; Kojima S; Mukae H; Yatera K; Takahashi K
    Biochem Biophys Rep; 2017 Mar; 9():86-94. PubMed ID: 28955993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
    Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
    Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.